S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

RGLS Regulus Therapeutics Inc

2.69

0.18 (7.17%)

Last Updated: 05:57:53

Delayed by 15 minutes

Regulus Therapeutics completes dosing in early-stage kidney disease trial

To read the full story on Seeking Alpha, click here.

Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Regulus Therapeutics Charts.

Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Regulus Therapeutics Charts.

Regulus Therapeutics Inc News

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Tuesday 30 April 2024 (2 days ago) • PR Newswire (US)

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Friday 22 March 2024 (1 month ago) • PR Newswire (US)

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Tuesday 12 March 2024 (2 months ago) • PR Newswire (US)

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Tuesday 12 March 2024 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 19 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 19 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 January 2024 (3 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Saturday 13 January 2024 (4 months ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Wednesday 10 January 2024 (4 months ago) • Edgar (US Regulatory)

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Wednesday 3 January 2024 (4 months ago) • PR Newswire (US)

Form S-3 - Registration statement under Securities Act of 1933
Thursday 28 December 2023 (4 months ago) • Edgar (US Regulatory)

More Regulus Therapeutics Inc News Articles

Gold vs US Dollar

JP Morgan Chase

Verizon Communications

Commonwealth Bank Of Aus...

Woodside Petroleum

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions